MR imaging of Hippel-Lindau disease: value of gadopentetate dimeglumine.

Hippel-Lindau disease is an autosomal dominant disorder characterized by tumors of the central nervous system and abdominal viscera. Frequent multisystem radiologic evaluation of persons at risk is desirable. Twenty-seven patients with Hippel-Lindau disease or a family history of the disease were examined with both unenhanced and gadopentetate dimeglumine-enhanced magnetic resonance (MR) imaging to study the usefulness of the contrast medium in the evaluation of these patients. The MR studies were correlated with computed tomographic (CT) scans in seven patients and cerebral angiograms in five. Twelve patients had hemangioblastomas in the brain, and eight of these patients also had spinal cord lesions (most were multiple), well demonstrated with gadopentetate dimeglumine. Contrast-enhanced MR imaging enabled detection of more central nervous system lesions and provided better delineation than unenhanced MR imaging, CT, or angiography. In addition, four patients with multiple renal cysts seen on CT scans and unenhanced MR images had enhancing lesions that were later proved to be renal cell carcinoma at angiography and/or surgery. Four patients had cystic lesions in the pancreas that did not enhance and were later proved to be pancreatic cysts. The authors conclude that gadopentetate dimeglumine-enhanced MR imaging appears to be a useful method for evaluating and following up patients with Hippel-Lindau disease.     

Rectal barium in pelvic MR imaging: initial results.

Pelvic magnetic resonance (MR) imaging is limited by lack of an effective bowel contrast agent. This study was performed to evaluate the efficacy of rectally administered barium sulfate as a contrast agent in pelvic MR imaging. Thirty-two patients were studied retrospectively to evaluate anatomic definition of the rectosigmoid colon. A commercially available barium sulfate suspension was administered rectally in 19 patients. Thirteen patients were imaged without barium. In the latter patients, anatomic definition of the rectum and sigmoid colon was poor to fair with all pulse sequences. Delineation of the rectum and sigmoid colon improved in patients who received rectal barium, owing to distention and marking of the bowel by the predominantly low-signal-intensity barium. Barium is a safe, inexpensive negative contrast agent for bowel that may improve pelvic MR imaging.     

Dynamic gadopentetate dimeglumine-enhanced MR imaging of hepatocellular carcinoma

Nineteen patients with 28 histologically proven hepatocellular carcinomas (HCCs) were examined using T1- and T2-weighted spin-echo sequences and dynamic gadopentetate dimeglumine-enhanced magnetic resonance imaging (MRI) performed by fast T1-weighted gradient-echo sequence (100/5/80°) which was performed before and repeatedly (12 sets of images) after intravenous bolus injection of gadopentetate dimeglumine (Gd-DTPA) over a period of 10 min. Enhancement of HCC was heterogeneous in 24 lesions (85.7%). Intra-lesional non-enhancing areas were seen in 18 cases (64%). A late-enhancing pseudocapsule was seen in 12 lesions (42.9%). In addition, two groups were distinguished in the examined HCCs: 16 lesions (57.1%) showed stronger enhancement compared to liver parenchyma with maximum positive lesion-to-liver contrast on the 15-s images, while 12 lesions (42.9%) had an enhancement less than normal liver with a maximum negative contrast on the 15-s images. We conclude that the morphologic features most frequently encountered in HCC on dynamic Gd-DTPA-enhanced MRI are inhomogeneity of enhancement, intra-lesional non-enhancing areas, and relatively late enhancement of a pseudocapsule. Taking the degree of enhancement to be representative of the degree of vascularity, we also conclude that HCC can appear either hypervascular or hypovascular in the early phase of the dynamic study. Correspondence to: B. Hamm     

Measurement of renal transit of gadopentetate dimeglumine with echo-planar MR imaging

Times of peak gadolinium concentration ([Gd]) after intravenous (IV) and left ventricular (LV) bolus injection of gadopentetate dimeglumine were determined in renal cortex and medulla in normal rabbits and in rabbits after saline load (overhydration) or hemorrhage (dehydration). Magnetic resonance images were obtained with echo-planar inversion-recovery sequences, and signal intensity-versus-time curves in cortical and medullary regions of interest were converted to [Gd]-versus-time curves. Cortical perfusion measured with microspheres demonstrated that the three physiologic states were significantly different. There were three separate [Gd] peaks in both the cortex and medulla as the bolus moved from one anatomic compartment to the next. The first cortical peak occurred sooner after LV than after IV bolus injection (P <.05) and later in dehydrated than in normal and overhydrated rabbits (P <.05). The first medullary peak always followed the first cortical peak by about 6–10 seconds and mirrored the cortical patterns. The second and third cortical peaks were consistent with proximal and distal tubular transit. These peaks similarly showed faster response to LV than IV injection and were delayed by hemorrhage. The authors conclude that quantitative physiologic information can be obtained with dynamic contrast-enhanced MR imaging of the kidney.     

MR imaging of soft-tissue masses: Role of gadopentetate dimeglumine

To assess the effectiveness of gadopentetate dimeglumine in the magnetic resonance (MR) imaging evaluation of soft-tissue masses without osseous involvement, 30 patients underwent MR imaging before and after administration of contrast material (0.1 mmol/ kg) of the 30 lesions, 22 were benign and eight were malignant; histologic confirmation was available in all lesions except one benign lesion. Overall, enhancement was detected in 26 (87%) of 30 lesions: 18 (82%) of the 22 benign lesions and eight (100%) of eight malignant lesions. Enhancement was characterized as homogeneous (two [11%] benign lesions, two [25%] malignant lesions), inhomogeneous (11 [61%] benign lesions, six [75%] malignant lesions), or peripheral (five [28%] benign lesions, no malignant lesions) of the 19 lesions assessed for a change in enhancement over time, seven (37%) showed an increase and two (11%) showed a decrease in signal intensity. The authors conclude that benign and malignant soft-tissue lesions could not be differentiated solely on the basis of enhancement (pattern, degree, or time course).     

MR portography: Preliminary comparison with CT portography and conventional MR imaging

Magnetic resonance (MR) imaging with arterial portography (MRAP) was compared with computed tomography with arterial portography (CTAP) and conventional MR imaging for preoperative evaluation of hepatic masses in eight patients (nine studies). Twenty contiguous, 10-mm-thick-section CTAP images were obtained. MR imaging included T1- and T2-weighted spin-echo and fast multiplanar SPGR (spoiled gradient-recalled acquisition in the steady state) techniques. For MRAP, 0.1 mmol/kg gadopentetate dimeglumine was injected into the superior mesenteric artery. Portographic-phase, 8-mm-thick-section, axial SPGR images were first obtained, followed by “systemic phase” SPGR images. Lesions were seen best on the portographic-phase MRAP images and were less conspicuous on the systemic-phase MRAP, CTAP and conventional MR images. Of 19 visualized lesions, 18 were seen with MRAP; however; five subcentimeter lesions seen with MRAP were not seen with conventional MR imaging or CTAP. Systemic recirculation of iodinated contrast material from the bolus and from previous angiography is a potential limitation of CTAP. For both CTAP and MRAP, optimal results are expected if all images are obtained during a single breath hold, within seconds of the onset of contrast agent administration.     

Diagnostic value of gadopentetate dimeglumine for 1.5-T MR imaging of musculoskeletal masses: comparison with unenhanced T1- and T2-weighted imaging.

Three magnetic resonance (MR) imaging techniques (T1-weighted, T2-weighted, and T1-weighted gadopentetate dimeglumine--enhanced) were compared in 32 consecutive MR imaging studies of 26 patients with suspected musculoskeletal masses. T2-weighted images were superior to T1-weighted enhanced images with respect to detection and definition of lesions in 12% of cases (n = 4) and were equal in 88% of cases (n = 28). T2-weighted images were also superior to T1-weighted images in 38% of cases (n = 12). In no cases were T1-weighted enhanced images superior to T2-weighted images. In two cases, T1-weighted images were superior to both T1-weighted enhanced and T2-weighted images. The authors conclude that gadopentetate dimeglumine did not provide much value in lesion detection above that obtained with T2-weighted images. They also conclude that T1-weighted images were occasionally superior to T1-weighted enhanced images and T2-weighted images because of loss of definition between fat and lesion on the latter.     

Contrast-enhanced MR angiography of the run-off vasculature: intraindividual comparison of gadobenate dimeglumine with gadopentetate dimeglumine

PURPOSE: To compare intraindividually gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for multi-station MR Angiography of the run-off vessels. MATERIALS AND METHODS: Twenty-one randomized healthy volunteers received either Gd-BOPTA or Gd-DTPA as a first injection and then the other agent as a second injection after a minimum interval of 6 days. Each agent was administered at a dose of 0.1 mmol/kg bodyweight followed by a 25-mL saline flush at a single constant flow rate of 0.8 mL/second. Images were acquired sequentially at the level of the pelvis, thigh, and calf using a fast three-dimensional (3D) gradient echo sequence. Source, subtracted source, maximum intensity projection (MIP), and subtracted MIP image sets from each examination were evaluated quantitatively and qualitatively on a segmental basis involving nine vascular segments. RESULTS: Significantly (P < 0.05) higher signal-to-noise and contrast-to-noise ratios were noted for Gd-BOPTA compared to Gd-DTPA, with the more pronounced differences evident in the more distal vessels. Qualitative assessmentrevealed no differences in the abdominal vasculature, a preference for Gd-BOPTA in the pelvic vasculature, and markedly better performance for Gd-BOPTA in the femoral and tibial vasculature. Summation of individual diagnostic quality scores for each segment revealed a significantly (P = 0.0001) better performance for Gd-BOPTA compared to Gd-DTPA. CONCLUSION: Greater vascular enhancement of the run-off vasculature is obtained after Gd-BOPTA, particularly in the smaller more distal vessels. Enhancement differences are not merely dose dependent, but may be due to different vascular enhancement characteristics of the agents.     

Comparison of Gadomer-17 and gadopentetate dimeglumine for differentiation of benign from malignant breast tumors with MR imaging

RATIONALE AND OBJECTIVES: This study compared gadopentetate dimeglumine (molecular weight, 0.5 kD), a standard contrast medium, and Gadomer-17 (apparent molecular weight, approximately 35 kD), a new, clinically applicable, large-molecular contrast medium, with respect to their microvascular characterizations of experimentally induced breast tumors at magnetic resonance (MR) imaging. MATERIALS AND METHODS: A spectrum of breast tumors, benign through highly malignant, was induced in Sprague-Dawley rats (n = 30) by intraperitoneal administration of N-ethyl-N-nitrosourea (ENU), a potent carcinogen. All animals underwent three-dimensional spoiled gradient-recalled MR imaging, with precontrast imaging and dynamic postcontrast imaging after injection of gadopentetate dimeglumine (0.1 mmol/kg) and Gadomer-17 (0.03 mmol/kg), administered in a random order at a 24-hour interval. Several microvascular parameters were compared: the endothelial transfer coefficient (K(PS)), a measure of microvascular permeability; the fractional plasma volume (fPV), and the plasma equivalent volume. Each MR imaging parameter was correlated with histopathologic findings. RESULTS: With Gadomer-17, the mean values for K(PS) and fPV were significantly greater in carcinomas than in fibroadenomas (P < .004 and .04, respectively). With gadopentetate dimeglumine, the mean values for fPV and PEV were significantly greater in carcinomas (P <. 004 and .02, respectively). Because of the high variability within both fibroadenoma and carcinoma groups, however, there were no significant correlations between K(PS), fPV, or PEV and histopathologic tumor grade as indicated by the Scarff-Bloom-Richardson score, for either agent. CONCLUSION: Although the K(PS) and fPV estimates obtained from dynamic MR imaging data with Gadomer-17 enhancement offer some potential for characterizing breast tumors, none of the quantitative microvascular parameters derived with either agent were significantly correlated with histopathologic tumor grade.     

Effect on fetal mouse development of exposure to MR imaging and gadopentetate dimeglumine

Pregnant mice were exposed to one of five regimens at 9.5 days of gestation: no treatment (group 1), intraperitoneal injection of normal saline (group 2), intraperitoneal injection of gadopentetate dimeglumine (group 3), intraperitoneal injection of gadopentetate dimeglumine and magnetic resonance (MR) exposure (group 4), and MR exposure alone (group 5). At 18 days of gestation, the mice were sacrifice and fetuses were removed and examined for the following end points: litter size, number alive or dead, fetal weight, extremity morphology, eye and ear development, and appearance of the head. A total of 739 fetuses were analyzed: group 1 (n = 161), group 2 (n = 149), group 3 (n = 142), group 4 (n = 136), and group 5 (n = 151). The only statistically significant difference was a lower mean fetal weight in the saline-injection group compared with the control group. The results show that MR exposure with and without gadopentetate dimeglumine had no adverse effect on the end points analyzed.     

Preoperative local staging of rectal carcinoma with MR imaging and a rectal balloon

Magnetic resonance (MR) imaging for the preoperative assessment of rectal carcinoma was evaluated. Thirty-three patients underwent MR imaging with a 1.5-T unit. On the basis of results of barium enema studies and/or digital examination, a balloon catheter was inserted to the level of the lesion before MR imaging. Both T1-and T2-weighted axial spin-echo images were obtained in all patients. With the balloon catheter, the three layers of the normal bowel wall could be seen on T2-weighted images. Muscular invasion was detected with a sensitivity of 90%, a specificity of 84%, a positive predictive value of 90%, a negative predictive value of 84%, and an overall accuracy of 88%. False-positive results were related to chemical shift artifact and intramural lymph node metastases. Perirectal fat invasion was detected with a sensitivity of 64%, a specificity of 89%, a positive predictive value of 82%, a negative predictive value of 77%, and an overall accuracy of 79%. One of the false-positive results was related to intramural lymph node metastases and the other to perirectal vessels. Evaluation of adjacent organ invasion was accurate in all patients. Lymph node metastasis was correctly detected in six of nine patients. Absence of lymph node metastasis was correctly predicted in 23 of 24 patients. Thus, MR imaging with a balloon catheter was useful for detection of tumor invasion into muscularis propria and adjacent organs; however, its demonstration of perirectal fat and lymph node involvement was less accurate.     

Bowel disease: prospective comparison of CT and 1.5-T pre- and postcontrast MR imaging with T1-weighted fat-suppressed and breath-hold FLASH sequences.

The potential of new high-field-strength magnetic resonance (MR) imaging sequences to evaluate bowel disease was investigated and compared with computed tomographic (CT) studies. Thirty-two patients were studied, 14 with known or suspected gastrointestinal tumors and 18 with known or suspected bowel inflammatory conditions. T1-weighted fat-suppressed spin-echo and breath-hold FLASH (fast low-angle shot) images were obtained before and after intravenous injection of 0.1 mmol/kg gadopentetate dimeglumine. Pathologic confirmation was obtained by biopsy (n = 18), surgical excision (n = 8), or endoscopy (n = 6). CT and MR images were analyzed separately in a prospective fashion and reviewed by consensus. Information from CT and MR images was comparable in cases of confirmed bowel neoplasia. CT scans had better spatial resolution, while fat-suppressed gadolinium-enhanced MR images had better contrast resolution. In the 18 cases of bowel inflammation, CT scans showed concentric wall thickening in 16, while MR images showed concentric wall thickening in 14 and increased contrast enhancement in 17. Contrast enhancement was better appreciated on fat-suppressed images than on FLASH images. The results suggest that MR imaging may play a role in the evaluation of bowel disease.     

MR imaging of uterine cervical carcinoma: comparison between fast spin-echo MRI and GRASE

The aim of our study was to compare the image quality of T2-weighted gradient-echo-and-spin-echo (GRASE) MRI and fast spin-echo (FSE) MRI for imaging of cervical carcinoma. In 40 patients FSE₈ (TR/TE = 3400/90 ms) MRI with echo train length (ETL) of 8, GRASE (3400/90) MRI with ETL of 18, turbo factor of 6 and 3 gradient reversals, and FSE₁₈ (2500/120) MRI with ETL of 18 were performed. Tissue contrast, subjectively rated image quality, and accuracy of tumor delineation were compared. Surgical correlation was obtained in 27 subjects. Contrast-to-noise ratios of the tumor–cervix stroma, tumor–parametrium and tumor–rectum wall interfaces were better in FSE₁₈ than in FSE₈ and GRASE (P < 0.001) but not different between FSE₈ and GRASE. Subjective image quality was better in FSE₁₈ and FSE₈ than in GRASE (P < 0.02). The accuracy of tumor delineation was similar for the three different sequences. The accuracy of FSE and GRASE MRI for the delineation of cervical carcinoma is similar. Based on measurement of image quality and CNRs, however, high turbo factor FSE provides better image quality in MRI of cervical carcinoma.Whether the superior characteristics may result in better staging has to be explored in larger clinical trials. Received 25 March 1997; Revision received 20 June 1997; Accepted 23 June 1997     

Renal cancer staging: Comparison of contrast-enhanced CT and gadolinium-enhanced fat-suppressed spin-echo and gradient-echo MR imaging

Fifty-three consecutive patients with 61 solid or complex non-fat-containing renal masses compatible with renal cancer were examined with contrast-enhanced computed tomography (CT) and magnetic resonance (MR) imaging with pre- and postcontrast FLASH (fast low-angle shot) and fat-suppressed spin-echo sequences. CT and MR imaging were performed within a 1-month interval. CT and MR images were prospectively interpreted. Tumor detection and staging were determined in all patients. CT and MR imaging enabled detection of 54 and 58 of 61 renal tumors, respectively. CT and MR imaging showed 34 and 35 of 38 histologically proved renal tumors, respectively, in 31 patients. Tumor size on CT and MR images demonstrated good correlation and correlated well with the size of pathologic specimens of 34 of 38 resected tumors detected with CT and MR imaging (r =.99). Of the 31 tumors in 31 patients who underwent surgical resection, 24 were correctly staged with CT and 29 with MR imaging. CT and MR imaging both enabled correct staging of four of five additional tumors with biopsy proof of tumor stage. A moderate difference in staging was observed between CT and MR imaging (P =.05). CT showed 13 and MR imaging 15 of 15 tumor thrombi. CT and MR imaging both showed 11 of 11 cases of adenopathy. The results suggest that MR imaging is moderately better than CT for the detection and staging of renal cancer.     

Gadobenate dimeglumine (BOPTA) enhanced MR imaging: Patterns of enhancement in normal liver and cirrhosis

To determine whether gadobenate dimeglumine (BOPTA) will adequately enhance cirrhotic liver parenchyma, and to document the enhancement patterns in cirrhosis, 14 cirrhotic and 20 non-cirrhotic patients were evaluated before and 60–120 minutes after gadolinium-BOPTA. Proof of liver cirrhosis was biopsy (6), surgical resection (3), and clinical follow-up (5). Enhancement effects were compared quantitatively by determining the liver signal-to-noise ratio (SNR) and signal enhancement in both populations. Qualitatively assessment of the liver enhancement was performed and classified as homogeneous or heterogeneous. Quantitative analysis: cirrhotic liver parenchyma presented a higher increase in SNR values, relative to noncirrhotic liver parenchyma, on postcontrast images. Likewise the signal enhancement of cirrhotic liver parenchyma was superior to non-cirrhotic liver on T1-weighted SE images (P = .02) and in-phase GRE images (P < .001). There was no statistical difference on out-of-phase GRE images. Qualitative analysis: on T1-weighted SE postcontrast images, cirrhotic liver parenchyma showed a homogeneous enhancement in 7 patients and heterogeneous in 7. Whereas on GRE images, cirrhotic parenchyma showed heterogeneous enhancement in 9 patients and homogeneous in 5 patients. The heterogeneous enhancement was due to the presence of hypointense nodules in 7 patients and hyperintense nodules in 2 patients. In conclusion, our study has shown that the hepatobiliary contrast agent Gd-BOPTA is effective in the cirrhotic liver, demonstrating an increased liver enhancement compared with non-cirrhotic patients.     

Evaluation of adrenal masses with gadolinium enhancement and fat-suppressed MR imaging

A study was undertaken to determine the ability to characterize benign and malignant masses with unenhanced and contrast material-enhanced fast lowangle shot and fat-suppressed spin-echo magnetic resonance (MR) imaging. Thirty patients with adrenal masses detected at computed tomography (CT) underwent MR imaging within 14 days after CT. CT and MR images were interpreted in a prospective, blinded fashion. Sixteen patients had 20 benign adrenal masses, and 14 patients had 18 malignant masses. Quantitative measurements included percentage of contrast enhancement on immediate postcontrast dynamic images and periphery - center signal-to-noise ratio (S/N) on gadolinium-enhanced fat-suppressed images. Qualitative evaluation included determination of the regularity of lesion margins, homogeneity of signal intensity, and local extension. MR imaging depicted all adrenal masses discovered at CT examinations. Lesions ranged in diameter from 1 to 15 (mean, 4.4) cm. No significant difference was observed in percentage of contrast enhancement between benign (90.5% ± 59.0 [standard deviation]) and malignant (110.5% ± 116.4) masses. A difference was observed between periphery - center S/N for benign (?.05 ± 1.5) and malignant (7.7 ± 9.8) masses; overlap between the two, however, occurred. Qualitative evaluation allowed correct characterization of 32 of 38 masses, comparing favorably with CT, which allowed characterization of 30 lesions.     

Theoretical analysis of gadopentetate dimeglumine enhancement in T1-weighted imaging of the brain: Comparison of two-dimensional spin-echo and three-dimensional gradient-echo sequences

By using a theoretical model, the signal difference-to noise ratios between simulated lesions and normal white matter and gray matter were calculated as a function of lesion concentration of gadopentetate dimeglumine (GD) for two-dimensional (2D) T1-weighted spin-echo (SE), three-dimensional (3D) steady-state spoiled gradient-echo (GRE) (FLASH [fast low-angle shot]), and 3D magnetization-prepared rapid gradient echo (MP-RAGE) pulse sequences. The 3D GRE sequences provided greater contrast enhancement at relatively high [GD], and the 2D SE sequence demonstrated greater enhancement and a higher rate of enhancement at low [GD]. The results predict that at low [GD], certain lesions could probably be detected with the 2D SE sequence but possibly not with one or both of the 3D GRE sequences. At high [GD], certain lesions could probably be detected with one or both of the 3D GRE sequences but possibly not with the 2D SE sequence. This provides a potential explanation for the clinical observation that certain contrast agent enhanced lesions appear less conspicuous on 3D GRE images than on 2D SE images and vice versa. Modified parameter values were derived for the 3D FLASH and 3D MP-RAGE sequences that are predicted to produce contrast enhancement behavior equivalent or superior to that of a conventional 2D SE sequence.     

T2-weighted MR imaging of focal hepatic lesions: Comparison of various RARE and fat-suppressed spin-echo sequences

The authors prospectively compared four T2-weighted magnetic resonance (MR) sequences, including high-resolution 512 × 512 (matrix size) RARE (rapid acquisition with relaxation enhancement), 256 × 256 RARE, 128 × 256 breath-hold RARE, and 192 × 256 fat-suppressed spin-echo (T2FS) sequences, in the evaluation of 16 patients with focal hepatic masses. MR images were evaluated by quantitative lesion-liver signal difference-to-noise ratios (SDNRs) and subjective evaluation of image artifact and image quality. No significant differences were observed between RARE sequences in SDNR values. The T2FS sequence had a significantly higher SDNR than the 512 × 512 RARE sequence (24.6 ± 15.0 vs 14.5 ± 9.7) (P =.008). Image quality was rated highest for the 512 × 512 RARE and T2FS sequences (P =.006). The inherent advantage of high spatial resolution suggests that the 512 × 512 RARE sequence may be of value in detecting hepatic lesions.